Skip to content
‹ Back to IndustriesSciences

Virgin Galactic Holdings CEO Michael Colglazier on Space Test Flights

Virgin Galactic Holdings’ recent successful launch rocketed confidence in the viability of commercial space travel. Watch below to see CEO Michael Colglazier react to the launch and comment on efforts to move towards commercial space tourism. Colglazier: We had three big points we were trying to do in this test flight, the first was to…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Sciences · · BloombergCommercial Space TravelMichael ColglazierSpace
Share

Key takeaways

01

Virgin Galactic Holdings’ recent successful launch rocketed confidence in the viability of commercial space travel.

02

Watch below to see CEO Michael Colglazier react to the launch and comment on efforts to move towards commercial space tourism.

03

Colglazier: We had three big points we were trying to do in this test flight, the first was to…

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

Virgin Galactic Holdings’ recent successful launch rocketed confidence in the viability of commercial space travel. Watch below to see CEO Michael Colglazier react to the launch and comment on efforts to move towards commercial space tourism.

Colglazier: We had three big points we were trying to do in this test flight, the first was to test a new set of digital controllers that we have for the pilots, give them tighter steering. It worked flawlessly. It went really well as it curved just straight up into space and beautiful flight. Second thing we were doing was to ensure that we had the electromagnetic interference issue from earlier in the year and all the work that we had done on that completely eliminated that problem for us. And then finally, we collected data that we sent over to the FAA and we believe that will give us a great opportunity for them to analyze it, and then hopefully clear our license for commercial flights. So, all in all, just a beautiful day.

Host: Michael, it’s Guy in London. So what’s the journey between now and that points that license being achieved? What needs to happen? When’s the next flight? And what sort of milestones does that. Next slide have to achieve?

Colglazier: Sure well, this was our third flight to space with humans, the first from the state of New Mexico, which is a beautiful, beautiful place to look back down upon the planet. And what follows next. We have three more flights in our test flight program. Our next one will come up with a full crew of mission specialists and back. In addition to our two pilots, that one will be followed with a repeat. But we’re asking our founder, Richard Branson, to come on and really test the private astronaut experience for us. We think, who better to do that? And both of those, we expect to happen this summer. And then that will be followed by our final test flight that’s planned with the Italian Air Force really showcasing how our space systems used for microgravity science research as well as professional astronaut training. And we think that will likely happen late summer or early fall.

Host: So let’s get to that in terms of the preflight training. So we’re going back and forth on this. How healthy do you have to be? What kind of training does there have to be for a regular person to eventually book a flight on this?

Colglazier: So what’s really unique about Virgin Galactic is we take the first 50,000 feet or so with airplane technology. So we take off horizontally and our mother ship climbs out to 40, 45, 50,000 feet. And then from there, the spaceship drops and then rockets up. So it’s powerful, but reasonably smooth because we’ve gone through the heaviest part of the atmosphere, just like you would in a commercial airliner. It’s really important to stay fit in general, but it’s not something that needs years and years of training. So we recommend people stay flexible because they want to be moving around in a weightless environment and kind of looking out all the windows. But generally, we think as long as people are taking care of themselves, lots and lots and lots of people will be able to go with us.

Host: OK, so not much training, Alex was concerned that I was getting a little bit old, maybe I was working so hard to think about. Let’s talk about price. In terms of this venture going forward, Michael. This is a question that I’m surprised I’m asking, but I guess we’ve got to think about it going forward, what is the path to profitability? When do you think this is profitable? Once it starts getting up and running and you kind of get through the initial kind of phase on this and this becomes more commonplace. You got to be making money off this. When do you think you’re going to be making money off this?

Colglazier: Well, the first thing we need to do, obviously, finish this test flight program. And then move into commercial service. And we believe this is going to be a supply constrained business for quite some time. The demand of this is going to be well out in front of our ability to build and scale the fleet up for a while. And as such, it will be reasonably expensive as it goes forward. Our previous 600 people generally had a price around $250,000 each. We have not announced what our pricing will be going forward. We said it will be higher in the beginning. We do see pricing of around $600,000 for per seat equivalent for our microgravity research flights. But again, we have not put pricing out for the private astronaut market.

*Bloomberg contributed to this content

—

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Video TranscriptExpand ↓

We had three big points we were trying to do in this test flight, the first was to test a new set of digital controllers that we have for the pilots, give them tighter steering. It worked flawlessly. It went really as it curved just straight up into space and beautiful flight. Second thing we were doing was to ensure that we had the electromagnetic interference issue that had the latest from earlier in the year and all the work that we had done on that completely eliminated that problem for us. And then finally, we collected data that we sent over to the FAA and we believe that will give us a great opportunity for them to analyze it, and then hopefully clear our license for commercial flights. So, all in all, just a beautiful day. Michael, it's guy in London. So what's the journey between now and that points that license being achieved? What needs to happen? When's the next flight? What does that. And what sort of milestones does that. Next slide have to achieve? Sure well, this was our third flight to space with humans, the first from the state of New Mexico, which is a beautiful, beautiful place to look back down upon the planet. And what follows next. We have three more flights in our test flight program. Our next one will come up with a full crew of mission specialist and back. In addition to our two pilots, that one will be followed with a repeat. But we're asking our founder, Richard Branson, to come on and really test the private astronaut experience for us. We think, who better to do that? And both of those, we expect to happen this summer. And then that will be followed by our final test flight that's planned with the Italian Air Force really showcasing how our space systems used for microgravity science research as well as professional astronaut training. And we think that will likely happen late summer or early fall. So let's get to that in terms of the preflight training. So we're going back and forth on this. How healthy do you have to be? What kind of training does there have to be for a regular person to eventually book a flight on this? So what's really unique about Virgin Galactic is we take the first $50,000 feet or so with Airplane technology, so we take off horizontally and our mother ship climbs out to 40, 45, 50,000 feet. And then from there, the spaceship drops and then rockets up. So it's powerful, but reasonably smooth because we've gone through the heaviest part of the atmosphere, just like you would in a commercial airliner. It's really important to stay fit in general, but it's not something that needs unique years and years of training. So we recommend people stay flexible because they want to be moving around in a weightless environment and kind of looking out all the windows. But generally, we think as long as people are taking care of themselves, lots and lots and lots of people will be able to go with us. OK, so not much training, Alex was concerned that I was getting a little bit old, maybe I was working so hard to think about. Let's talk about price in terms of this venture going forward, Michael. This is a question that I'm surprised I'm asking, but I guess we've got to think about it going forward, what is the path to profitability? When do you think this is profitable? Once it starts getting up and running and you kind of get through the initial kind of phase on this and this becomes more commonplace. You got to be making money off this. When do you think you're going to be making money off this? Well, the first thing we need to do, obviously, finish this test flight program. And then move into commercial service. And we believe this is going to be a supply constrained business for quite some time. The demand of this is going to be well out in front of our ability to build and scale the fleet up for a while. And as such, it will be reasonably expensive as it goes forward. Our previous 600 people generally had a price around 250,000 each. We have not announced what our pricing will be going forward. We said it will be higher in the beginning. We do see pricing of around $600,000 for per seat equivalent for our microgravity research flights. But again, we have not put pricing out for the private astronaut market.

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

S
Sciences
B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Sciences Insights

Antibody developability checks are moving into discovery instead of waiting for development

Antibody developability checks are moving into discovery instead of waiting for development

Maria Gonzalez-Pajuelo of FairJourney Bio says the order in antibody discovery is changing: developability has become a much more important consideration during discovery, rather than an issue left until later-stage development. The goal, she says, is that what comes out of discovery is something CMC can take forward easily.

  • 01Discovery-stage developability screens can rank many antibodies tested once or twice and may reduce surprises later in development, while development still focuses on several lots of a single antibody and answers different questions.

Oct 1, 2026

Caraballo expects AI across all five tracks at ISPE’s 2026 Annual Meeting

Caraballo expects AI across all five tracks at ISPE’s 2026 Annual Meeting

ISPE’s 2026 Annual Meeting and Expo in Washington, DC organizes its program around five tracks running from discovery to governance, with international program committee chair Connie Langer of Pfizer Global Supply and executive chair Jose Caraballo of JCO Global Advisory LLC describing how the tracks connect—and why AI is treated as a cross-cutting topic rather than a standalone track. Deloitte’s December 2025 survey of 280 executives frames the mood the program is built for.

  • 01ISPE’s 2026 Annual Meeting has no dedicated AI track; executive chair Jose Caraballo expects AI presentations across all five tracks, from discovery to governance.
  • 02Deloitte’s December 2025 survey of 280 biopharma and medtech C-suite executives found more than 75% confident in their own outlook but only 41% optimistic about the global economy, a mood the story says the ISPE chairs are programming for.
  • 03A staffing firm reports life sciences job openings falling even as digital fluency becomes a required skill, so the upskilling burden lands on the people already employed, which is where the mandatory, university-partnered AI training Connie Langer describes at her company sits.

Sep 30, 2026

Crown Bioscience's San Diego site fits the tumor model to the therapy, not the reverse

Crown Bioscience's San Diego site fits the tumor model to the therapy, not the reverse

Crown Bioscience's San Diego site designs preclinical tumor models to match specific therapies and delivery routes, rather than forcing treatments into standard study designs. It combines custom surgical procedures, cell line-derived xenografts, patient-derived xenografts (including post-treatment models), and biomarker capabilities to generate translational data that can help sponsors decide whether to advance a program.

  • 01Orthotopic brain tumor implantation using tagged models lets researchers track tumor growth in the original organ, aligning the model and delivery route with how therapies are intended to be tested.
  • 02Patient-derived xenografts developed from tumors after prior treatment may better reflect progressed disease, helping teams study therapies aimed at patients whose cancer has advanced after earlier treatment.
  • 03Combining biomarker analysis of preclinical model samples with clinical sample testing at one site could make it easier to connect what is measured in animals with what is later measured in patients.

Sep 30, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

S
Sciences

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512